EUVIMEDEUVIMED entdecken
Crossref

New molecularly targeted drugs for gist after imatinib, sunitinib and regorafenib: a narrative review

Alessandro Mazzocca, Alessandro Minelli, Flavia Paternostro, Marianna Silletta, Andrea Napolitano, Bruno Vincenzi

Gastrointestinal Stromal Tumor · 2022-05 · 5 · 4-4

DOI: 10.21037/gist-21-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2022-05. Verfasst von Alessandro Mazzocca und 5 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: Targeting KIT and PDGFRA with traditional tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib and regorafenib has revolutionized the treatment and the prognosis of patients diagnosed with locally advanced and metastatic gastrointestinal stromal tumors (GISTs) but resistance to those therapies represents a major challenge in the management of patients with progression disease after the third line. In this review we shed light on the latest updates about management options in GIST, discussing novel molecular compound, combination therapy and future prospects with further personalisation of treatment. Methods: A narrative review of the literature was performed to evaluate new systemic treatment options for patients with metastatic GIST. Randomized controlled trials, single-arm phase I–III trials and retrospective analyses were included by a PubMed research and were included studied published from 2008 to 2021. Key Content and Findings: Ninety-seven relevant articles were considered eligible and analyzed. As results, this review shows as the armamentarium of GIST therapy has been enriched of some new drugs. The INVICTUS trial, investigating fourth line Ripretinib achieved its primary endpoint, as in the double-blind period median progression-free survival (mPFS) of patients taking the experimental drug was 6.3 months [95% confidence interval (CI): 4.6–6.9 months] compared with 1.0 months of those receiving placebo (95% CI: 0.9–1.7 months) with a hazard ratio of 0.15 (95% CI: 0.09–0.25 months, P

Zitieren

APA

Mazzocca, A., Minelli, A., Paternostro, F., Silletta, M., Napolitano, A., & Vincenzi, B. (2022). New molecularly targeted drugs for gist after imatinib, sunitinib and regorafenib: a narrative review. Gastrointestinal Stromal Tumor, 5, 4-4. https://doi.org/10.21037/gist-21-6

Vancouver

Mazzocca A, Minelli A, Paternostro F, Silletta M, Napolitano A, Vincenzi B. New molecularly targeted drugs for gist after imatinib, sunitinib and regorafenib: a narrative review. Gastrointestinal Stromal Tumor. 2022;5:4-4. doi:10.21037/gist-21-6

BibTeX
@article{Mazzocca2022,
  author = {Mazzocca, Alessandro and Minelli, Alessandro and Paternostro, Flavia and Silletta, Marianna and Napolitano, Andrea and Vincenzi, Bruno},
  title = {New molecularly targeted drugs for gist after imatinib, sunitinib and regorafenib: a narrative review},
  journal = {Gastrointestinal Stromal Tumor},
  year = {2022},
  volume = {5},
  pages = {4--4},
  doi = {10.21037/gist-21-6}
}
Kostenlos starten →